Key questions regarding the SYMPLICITY HTN-3 trial

Lancet. 2023 Apr 22;401(10385):1336-1337. doi: 10.1016/S0140-6736(23)00340-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Blood Pressure
  • Humans
  • Hypertension* / drug therapy
  • Kidney
  • Sympathectomy

Substances

  • Antihypertensive Agents